Based on the Hydros-TA technology, Jingfeng plans to commercialize an intra-articular therapy, designed for treating the pain associated with osteoarthritis of the knee, in China.
In exchange for the license, Carbylan will receive an upfront payment, development and regulatory milestones, and commercialization milestones.
Carbylan president and chief executive officer George Daniloff said the agreement will provide the company with additional capital to fund the clinical development of its joint therapy products including Hydros-TA and Hydros.
"In addition, the resources of Jingfeng, including its own proprietary medical grade hyaluronic acid and its related commercial manufacturing capabilities, provide an opportunity for a broader future collaboration between the two companies in commercializing Carbylan products in global markets."
Hydros and Hydros-TA are investigational products and are not approved for use in the US or any other country.